L'azienda ospedaliera universitaria "Federico II", è una attività universitaria di Napoli, gestita dall'Università Federico II.

During the past decade, Azienda Ospedaliera Universitaria Federico II conducted 157 clinical trials. In the 10-year time frame, 157 clinical trials started and 48 clinical trials were completed, i.e. on average, 30.6% percent of trials that started reached the finish line to date. In the past 5 years, 72 clinical trials started and 40 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Federico II" #1 sponsor was "National Cancer Institute, Naples" with 10 trials, followed by "Celgene" with 9 trials sponsored, "Takeda" with 9 trials sponsored, "Eli Lilly and Company" with 8 trials sponsored and "Hoffmann-La Roche" with 8 trials sponsored. Other sponsors include 174 different institutions and companies that sponsored additional 119 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Federico II" #1 collaborator was "Eli Lilly and Company" with 5 trials as a collaborator, "Clinical Research Technology S.r.l." with 3 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 3 trials as a collaborator, "Takeda Development Center Americas, Inc." with 3 trials as a collaborator and "Incyte Corporation" with 2 trials as a collaborator. Other collaborators include 55 different institutions and companies that were collaborators in the rest 65 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Universitaria Federico II" are "Heart Failure" (10 trials), "Breast Cancer" (7 trials), "Coronary Artery Disease" (7 trials), "Acromegaly" (4 trials) and "Atrial Fibrillation" (4 trials). Many other conditions were trialed in "Azienda Ospedaliera Universitaria Federico II" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Universitaria Federico II" are "Drug" (151 trials), "Other" (19 trials), "Device" (18 trials), "Biological" (8 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (49 trials), "Carboplatin" (6 trials), "Paclitaxel" (6 trials), "Baricitinib" (5 trials) and "Gemcitabine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Universitaria Federico II" are 201 trials for "All" genders, 18 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Universitaria Federico II". 1 are not yet recruiting, 48 are recruiting, 34 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 103 completed trials in Azienda Ospedaliera Universitaria Federico II, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Universitaria Federico II, 2 "Phase 1" clinical trials were conducted, 47 "Phase 2" clinical trials and 97 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 19 trials that are defined as “Not Applicable".